383 related articles for article (PubMed ID: 25516806)
1. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade.
Lipson EJ; Velculescu VE; Pritchard TS; Sausen M; Pardoll DM; Topalian SL; Diaz LA
J Immunother Cancer; 2014; 2(1):42. PubMed ID: 25516806
[TBL] [Abstract][Full Text] [Related]
2. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
[TBL] [Abstract][Full Text] [Related]
4. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
[TBL] [Abstract][Full Text] [Related]
5. Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma.
Váraljai R; Wistuba-Hamprecht K; Seremet T; Diaz JMS; Nsengimana J; Sucker A; Griewank K; Placke JM; Horn PA; von Neuhoff N; Shannan B; Chauvistré H; Vogel FCE; Horn S; Becker JC; Newton-Bishop J; Stang A; Neyns B; Weide B; Schadendorf D; Roesch A
JCO Precis Oncol; 2020; 3():. PubMed ID: 32914028
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma.
Wong SQ; Raleigh JM; Callahan J; Vergara IA; Ftouni S; Hatzimihalis A; Colebatch AJ; Li J; Semple T; Doig K; Mintoff C; Sinha D; Yeh P; Silva MJ; Alsop K; Thorne H; Bowtell DD; Gyorki DE; Arnau GM; Cullinane C; Kee D; Brady B; Kelleher F; Dawson MA; Papenfuss AT; Shackleton M; Hicks RJ; McArthur GA; Sandhu S; Dawson SJ
JCO Precis Oncol; 2017 Nov; 1():1-14. PubMed ID: 35172485
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.
Cabel L; Riva F; Servois V; Livartowski A; Daniel C; Rampanou A; Lantz O; Romano E; Milder M; Buecher B; Piperno-Neumann S; Bernard V; Baulande S; Bieche I; Pierga JY; Proudhon C; Bidard FC
Ann Oncol; 2017 Aug; 28(8):1996-2001. PubMed ID: 28459943
[TBL] [Abstract][Full Text] [Related]
8. Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies.
McEvoy AC; Pereira MR; Reid A; Pearce R; Cowell L; Al-Ogaili Z; Khattak MA; Millward M; Meniawy TM; Gray ES; Ziman M
Oncotarget; 2019 Jan; 10(2):113-122. PubMed ID: 30719207
[TBL] [Abstract][Full Text] [Related]
9. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.
Tsao SC; Weiss J; Hudson C; Christophi C; Cebon J; Behren A; Dobrovic A
Sci Rep; 2015 Jun; 5():11198. PubMed ID: 26095797
[TBL] [Abstract][Full Text] [Related]
10. The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond
Marsavela G; Johansson PA; Pereira MR; McEvoy AC; Reid AL; Robinson C; Warburton L; Khattak MA; Meniawy TM; Amanuel B; Millward M; Hayward NK; Ziman MR; Gray ES; Calapre L
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33339135
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
12. Clearance of plasma cell free DNA in metastatic uveal melanoma with radiographic response to immune checkpoint inhibitors.
Francis JH; Barker CA; Canestraro J; Abramson DH; Shoushtari AN
Am J Ophthalmol Case Rep; 2024 Jun; 34():102021. PubMed ID: 38444640
[TBL] [Abstract][Full Text] [Related]
13. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma.
Bidard FC; Madic J; Mariani P; Piperno-Neumann S; Rampanou A; Servois V; Cassoux N; Desjardins L; Milder M; Vaucher I; Pierga JY; Lebofsky R; Stern MH; Lantz O
Int J Cancer; 2014 Mar; 134(5):1207-13. PubMed ID: 23934701
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors.
Pedersen JG; Madsen AT; Gammelgaard KR; Aggerholm-Pedersen N; Sørensen BS; Øllegaard TH; Jakobsen MR
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486146
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Value of a Single, Randomly Timed Circulating Tumor DNA Measurement in Patients with Metastatic Melanoma.
Boerlin A; Bellini E; Turko P; Cheng PF; Levesque MP; Dummer R; Ramelyte E
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077695
[TBL] [Abstract][Full Text] [Related]
16. Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer.
Beránek M; Sirák I; Vošmik M; Petera J; Drastíková M; Palička V
Acta Medica (Hradec Kralove); 2016; 59(2):54-8. PubMed ID: 27526306
[TBL] [Abstract][Full Text] [Related]
17. Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma.
Braune J; Keller L; Schiller F; Graf E; Rafei-Shamsabadi D; Wehrle J; Follo M; Philipp U; Hussung S; Pfeifer D; Mix M; Duyster J; Fritsch R; von Bubnoff D; Meiss F; von Bubnoff N
JCO Precis Oncol; 2020 Nov; 4():20-31. PubMed ID: 35050727
[TBL] [Abstract][Full Text] [Related]
18. Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study.
Herbreteau G; Vallée A; Knol AC; Théoleyre S; Quéreux G; Varey E; Khammari A; Dréno B; Denis MG
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920470
[TBL] [Abstract][Full Text] [Related]
19. Corresponding ctDNA and tumor burden dynamics in metastatic melanoma patients on systemic treatment.
Egger ME; Alexander E; Van Meter T; Kong M; Maung AA; Valdes R; Hall MB; Linder MW
Transl Oncol; 2024 Apr; 42():101883. PubMed ID: 38306914
[TBL] [Abstract][Full Text] [Related]
20. Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response.
Jia N; Sun Z; Gao X; Cheng Y; Zhou Y; Shen C; Chen W; Wang X; Shi R; Li N; Zhou J; Bai C
Front Genet; 2019; 10():470. PubMed ID: 31164904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
